An observational study in Psoriasis, sponsored by Khon Kaen University. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Khon Kaen University · Observational
Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability.
Although objective tools such as colorimeters provide accurate erythema measurement, their high cost limits routine clinical use. Smartphone imaging combined with artificial intelligence (AI) offers a practical alternative for objective assessment. However, variability in lighting conditions can affect image consistency. Incorporating a color calibration card enables accurate color normalization.
This study aims to develop and validate an AI-based system for measuring erythema in psoriatic lesions using smartphone images with a color card, compared against a standard colorimeter to assess validity and reliability.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's planned enrollment of 50 is below the median of 199 across 407 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Khon Kaen University is the lead sponsor of 161 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A dermatology clinic in Srinagarind Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is distinct from other clinical studies in that it does not involve any therapeutic intervention or modification of standard patient care. Instead, it evaluates a non-invasive, image-based measurement system that combines smartphone photography, a color calibration card, and artificial intelligence to quantify erythema in psoriasis lesions. Unlike conventional approaches that rely on subjective physician scoring or require specialized and costly equipment, this intervention is designed to be low-cost, accessible, and applicable in real-world settings, including patient self-monitoring at home.
To evaluate the accuracy of erythema measurements of psoriatic lesions obtained from an AI-based erythema model (smartphone imaging with a color calibration card) compared with a standard color calibration device (gold standard).
Time frame: From enrollment to 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.
Of 92 non-industry observational studies under Psoriasis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 119. This study's planned 5 months is below that.
Counting every sponsor, half of 173 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.